Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 7.2% – Here’s Why

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) traded down 7.2% during trading on Tuesday . The stock traded as low as $25.01 and last traded at $25.19. 54,928 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 257,588 shares. The stock had previously closed at $27.15.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Stock Down 7.9%

Insiders Place Their Bets

In related news, major shareholder Ra Capital Management, L.P. bought 6,387 shares of Hemab Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $24.90 per share, for a total transaction of $159,036.30. Following the acquisition, the insider owned 6,372,170 shares in the company, valued at $158,667,033. This trade represents a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders purchased 2,898,074 shares of company stock valued at $53,650,008.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.